Description

This issue of Vital Signs, released on June 21, 2010, provides a strategic analysis of trends in pulmonary drug delivery outside of respiratory diseases. Additionally, a company spotlight is provided for ZIOPHARM Oncology, a company focused on the research and development of small molecule therapies for the treatment of cancer. Reimbursement and regulatory news from the FDA is also provided for the week of May 31, 2010.